No cure yet for HIV-1, but therapeutic research presses on

Journal of Infectious Diseases

Volumn 195, Issue 6, 2007, Pages 770-772

  Schooley, Robert T ^a,c   Mellors, John W ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD28 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; HISTONE DEACETYLASE INHIBITOR; INTEGRASE INHIBITOR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; OKT 3; SMALL INTERFERING RNA; VALPROIC ACID;

DRUG RESEARCH; EDITORIAL; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS INHIBITION; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; RESEARCH; VALPROIC ACID; VIRUS REPLICATION;

EID: 33847652905     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/511830     Document Type: Editorial

References (17)

1. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833-6 (in this issue).
2. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-55.
3. Coffin I, Maldarelli F, Palmer S, et al. Long-term persistence of low-level HIV-1 in patients on suppressive antiretroviral therapy [abstract 169]. In: Program and abstracts of 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
4. Fischl MA, Richman DD, Grieco M, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. AZT Collaborative Working Group. N Engl J Med 1987; 317:185-91.
5. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-8.
6. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
7. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
8. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001; 285:1308-15.
9. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study [abstract 106LB]. In: Program and abstracts of 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
10. Christine D, Moh R, Sorho S, et al. The CD4-guided strategy arm stopped in a randomized structured treatment interruption trial in West-African Adults: ANRS 1269 Trivacan Trial [abstract 105LB]. ANRS 1269 Study Group. In: Program and abstracts of 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
11. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatments interruptions compared to continuous therapy: results of the Staccato Trial [abstract 102]. Staccato Study Group. In: Program and abstracts of 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
12. Hakim J. A structured treatment (STI) strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART Trial [abstract THBL0207]. DART Trial Team. In: Program and abstracts of the XVI International AIDS Conference (Toronto, Canada). Geneva: International AIDS Society, 2006.
13. Levy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. ANRS 093 Study Group. AIDS 2006; 20:405-13.
14. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80:4717-28.
15. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-28.
16. Prins JM, Jurriaans S, van Praag RM, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999; 13:2405-10.
17. van Praag RM, Prins JM, Roos MT, et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001; 21:218-26.